The DOI matches its Crossref record; 174 of the 174 references it cites were found in a registry or an index.
Denosumab and bisphosphonates: Different mechanisms of action and effects
Open accessAbstract
To treat systemic bone loss as in osteoporosis and/or focal osteolysis as in rheumatoid arthritis or periodontal disease, most approaches target the osteoclasts, the cells that resorb bone. Bisphosphonates are currently the most widely used antiresorptive therapies. They act by binding the mineral component of bone and interfere with the action of osteoclasts. The nitrogen-containing bisphosphonates, such as alendronate, act as inhibitors of farnesyl-pyrophosphate synthase, which leads to inhibition of the prenylation of many intracellular signaling proteins. The discovery of RANKL and the essential role of RANK signaling in osteoclast differentiation, activity and survival have led to the development of denosumab, a fully human monoclonal antibody. Denosumab acts by binding to and inhibiting RANKL, leading to the loss of osteoclasts from bone surfaces. In phase 3 clinical studies, denosumab was shown to significantly reduce vertebral, nonvertebral and hip fractures compared with placebo and increase areal BMD compared with alendronate. In this review, we suggest that the key pharmacological differences between denosumab and the bisphosphonates reside in the distribution of the drugs within bone and their effects on precursors and mature osteoclasts. This may explain differences in the degree and rapidity of reduction of bone resorption, their potential differential effects on trabecular and cortical bone, and the reversibility of their actions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670 · cited 3×
“In vitro, the combination of RANKL andM-CSF is required for optimal osteoclast survival [17].”
BackgroundOsteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Marx, R. E. (2003) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/s0278-2391(03)00720-1 · Cited by 3,036
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C., Rizzoli, R., Reginster, J.-Y., & on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,948
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,288
Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., et al. (1999) · Nature · doi:10.1038/46303 · Cited by 1,856 · cited 1×
“However, when RANKL is produced by activated T cells during inflammatory processes such as colitis and rheumatoid arthritis (RA) in the absence of other immune molecule deficits, antagonizing RANK/RANKL signaling has no effect on proliferation or activation of inflammatory cells [93–97].”
BackgroundYoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
RANK is essential for osteoclast and lymph node development.
Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478
Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy
Odvina, C. V., Zerwekh, J. E., Rao, D. S., Maalouf, N., Gottschalk, F. A., & Pak, C. Y. C. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0952 · Cited by 1,432
Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0540-8 · Cited by 1,411
Self-citationThe molecular understanding of osteoclast differentiation
Asagiri, M., & Takayanagi, H. (2007) · Bone · doi:10.1016/j.bone.2006.09.023 · Cited by 1,363
Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
Bone, H. G., Hosking, D., Devogelaer, J.-P., Tucci, J. R., Emkey, R. D., Tonino, R. P., Rodriguez-Portales, J. A., Downs, R. W., Gupta, J., Santora, A. C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030897 · Cited by 1,347
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Denosumab in postmenopausal women with low bone mineral density.
McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228
Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14363 · Cited by 1,184
Black, D. M., Greenspan, S. L., Ensrud, K. E., Palermo, L., McGowan, J. A., Lang, T. F., Garnero, P., Bouxsein, M. L., Bilezikian, J. P., & Rosen, C. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031975 · Cited by 1,174
Osteocytes, mechanosensing and Wnt signaling
Bonewald, L. F., & Johnson, M. L. (2008) · Bone · doi:10.1016/j.bone.2007.12.224 · Cited by 1,076
Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., & Rodan, G. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115539 · Cited by 1,004
Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis
Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P., Woodson, G. C., Yanover, M. J., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007123230201 · Cited by 949
Bisphosphonates: A review of their pharmacokinetic properties
Lin, J. H. (1996) · Bone · doi:10.1016/8756-3282(95)00445-9 · Cited by 932
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
Plotkin, L. I., Weinstein, R. S., Parfitt, A. M., Roberson, P. K., Manolagas, S. C., & Bellido, T. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6800 · Cited by 890 · cited 1×
“In contrast to the ability of bisphosphonates to induce osteoclast apoptosis, very low concentrations of several bisphosphonates seem to protect osteocytes (and osteoblasts) from glucocorticoid-induced apoptosis in vitro [80].”
BackgroundZebaze, R. M., Ghasem-Zadeh, A., Bohte, A., Iuliano-Burns, S., Mirams, M., Price, R. I., Mackie, E. J., & Seeman, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60320-0 · Cited by 865
Nancollas, G. H., Tang, R., Phipps, R. J., Henneman, Z., Gulde, S., Wu, W., Mangood, A., Russell, R. G. G., & Ebetino, F. H. (2006) · Bone · doi:10.1016/j.bone.2005.05.003 · Cited by 862
Self-citationRole of RANK ligand in mediating increased bone resorption in early postmenopausal women
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825 · cited 1×
“Increased expression and production of RANK ligand (RANKL), as seen with estrogen deprivation, is a central mechanism of osteoclast activation and increased bone resorption [8,9].”
BackgroundKearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
RANK-L and RANK: T Cells, Bone Loss, and Mammalian Evolution
Theill, L. E., Boyle, W. J., & Penninger, J. M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064753 · Cited by 819
Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis
Zhao, C., Irie, N., Takada, Y., Shimoda, K., Miyamoto, T., Nishiwaki, T., Suda, T., & Matsuo, K. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.05.012 · Cited by 777
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., Burlet, N., Cooper, C., Delmas, P. D., Reginster, J.-Y., Borgstrom, F., Rizzoli, R., & on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) · Osteoporosis International · doi:10.1007/s00198-008-0560-z · Cited by 776
Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040305 · Cited by 771
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.3.527 · Cited by 689
Mashiba, T., Hirano, T., Turner, C. H., Forwood, M. R., Johnston, C. C., & Burr, D. B. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.4.613 · Cited by 688
Theoleyre, S., Wittrant, Y., Tat, S. K., Fortun, Y., Redini, F., & Heymann, D. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.06.004 · Cited by 663
Osteoclast-derived activity in the coupling of bone formation to resorption
Martin, T. J., & Sims, N. A. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.12.004 · Cited by 659
Brown, J. P., Prince, R. L., Deal, C., Recker, R. R., Kiel, D. P., de Gregorio, L. H., Hadji, P., Hofbauer, L. C., Álvaro-Gracia, J. M., Wang, H., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0809010 · Cited by 610
Francis, M. D., Graham, R., Russell, G., & Fleisch, H. (1969) · Science · doi:10.1126/science.165.3899.1264 · Cited by 608
New Insights Into the Molecular Mechanisms of Action of Bisphosphonates
Rogers, M. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033453640 · Cited by 579
Miller, P. D., Bolognese, M. A., Lewiecki, E. M., McClung, M. R., Ding, B., Austin, M., Liu, Y., & San Martin, J. (2008) · Bone · doi:10.1016/j.bone.2008.04.007 · Cited by 578
Osteocyte Wnt/β-Catenin Signaling Is Required for Normal Bone Homeostasis
Kramer, I., Halleux, C., Keller, H., Pegurri, M., Gooi, J. H., Weber, P. B., Feng, J. Q., Bonewald, L. F., & Kneissel, M. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01428-09 · Cited by 567
Pederson, L., Ruan, M., Westendorf, J. J., Khosla, S., & Oursler, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805133106 · Cited by 556
Chavassieux, P. M., Arlot, M. E., Reda, C., Wei, L., Yates, A. J., & Meunier, P. J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119668 · Cited by 523
Aguirre, J. I., Plotkin, L. I., Stewart, S. A., Weinstein, R. S., Parfitt, A. M., Manolagas, S. C., & Bellido, T. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060107 · Cited by 494
Osteoimmunology and the effects of the immune system on bone
Takayanagi, H. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.217 · Cited by 487
The effect of a single dose of osteoprotegerin in postmenopausal women.
Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484
Elimination mechanisms of therapeutic monoclonal antibodies
Tabrizi, M. A., Tseng, C.-M. L., & Roskos, L. K. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03638-x · Cited by 478
Bisphosphonates in Bone Disease: From the Laboratory to the Patient
Fleisch, H. A. (1995) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 472
Kendler, D. L., Roux, C., Benhamou, C. L., Brown, J. P., Lillestol, M., Siddhanti, S., Man, H.-S., Martin, J. S., & Bone, H. G. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090716 · Cited by 453
Niida, S., Kaku, M., Amano, H., Yoshida, H., Kataoka, H., Nishikawa, S., Tanne, K., Maeda, N., Nishikawa, S.-I., & Kodama, H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.2.293 · Cited by 444
Kostenuik, P. J., Nguyen, H. Q., McCabe, J., Warmington, K. S., Kurahara, C., Sun, N., Chen, C., Li, L., Cattley, R. C., Van, G., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081112 · Cited by 443
Osteocytes as Dynamic Multifunctional Cells
BONEWALD, L. F. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.018 · Cited by 417
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.
Lacey, D. L., Tan, H. L., Lu, J., Kaufman, S., Van, G., Qiu, W., Rattan, A., Scully, S., Fletcher, F., Juan, T., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64556-7 · Cited by 391
Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy
Weinstein, R. S., Roberson, P. K., & Manolagas, S. C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0802633 · Cited by 391
Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL
Sobacchi, C., Frattini, A., Guerrini, M. M., Abinun, M., Pangrazio, A., Susani, L., Bredius, R., Mancini, G., Cant, A., Bishop, N., et al. (2007) · Nature Genetics · doi:10.1038/ng2076 · Cited by 389
Calvi, L. M., Sims, N. A., Hunzelman, J. L., Knight, M. C., Giovannetti, A., Saxton, J. M., Kronenberg, H. M., Baron, R., & Schipani, E. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11296 · Cited by 388
Self-citationBody, J.-J., Greipp, P., Coleman, R. E., Facon, T., Geurs, F., Fermand, J.-P., Harousseau, J.-L., Lipton, A., Mariette, X., Williams, C. D., et al. (2003) · Cancer · doi:10.1002/cncr.11138 · Cited by 383
Hak, A. E., Pols, H. A. P., van Hemert, A. M., Hofman, A., & Witteman, J. C. M. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.8.1926 · Cited by 375
Osteoprotegerin Reduces Osteoclast Numbers and Prevents Bone Erosion in Collagen-Induced Arthritis
Romas, E., Sims, N. A., Hards, D. K., Lindsay, M., Quinn, J. W. M., Ryan, P. F. J., Dunstan, C. R., Martin, T. J., & Gillespie, M. T. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64417-3 · Cited by 368
Abrahamsen, B., Eiken, P., & Eastell, R. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081247 · Cited by 366
Perazella, M. A., & Markowitz, G. S. (2008) · Kidney International · doi:10.1038/ki.2008.356 · Cited by 363
Fuller, K., Owens, J. M., Jagger, C. J., Wilson, A., Moss, R., & Chambers, T. J. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.5.1733 · Cited by 362
Hughes, D. E., MacDonald, B. R., Russell, R. G., & Gowen, M. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114100 · Cited by 357
Self-citationTwo modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.
Boonekamp, P. M., van der Wee-Pals, L. J. A., LENNEP, M. V., Cw, T., & Bijvoet, O. L. (1986) · PubMed · Cited by 345
Skeletal Benefits of Alendronate: 7-Year Treatment of Postmenopausal Osteoporotic Women1
Tonino, R. P., Meunier, P. J., Emkey, R., Rodriguez-Portales, J. A., Menkes, C.-J., Wasnich, R. D., Bone, H. G., Santora, A. C., Wu, M., Desai, R., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.9.6777 · Cited by 335
Fleisch, H. A., Russell, R. G. G., Bisaz, S., Mühlbauer, R. C., & Williams, D. A. (1970) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1970.tb00591.x · Cited by 325
Self-citationMiller, P. D., Roux, C., Boonen, S., Barton, I. P., Dunlap, L. E., & Burgio, D. E. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050817 · Cited by 318
Human Osteoclast-Poor Osteopetrosis with Hypogammaglobulinemia due to TNFRSF11A (RANK) Mutations
Guerrini, M. M., Sobacchi, C., Cassani, B., Abinun, M., Kilic, S. S., Pangrazio, A., Moratto, D., Mazzolari, E., Clayton-Smith, J., Orchard, P., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.06.015 · Cited by 309
Bennett, B. J., Scatena, M., Kirk, E. A., Rattazzi, M., Varon, R. M., Averill, M., Schwartz, S. M., Giachelli, C. M., & Rosenfeld, M. E. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000236428.91125.e6 · Cited by 304 · cited 1×
“Inactivation of the OPG gene in ApoE knockout mice, which are prone to atherosclerosis and vascular calcification, increased each of these vascular phenotypes [112].”
BackgroundPrice, P. A., Faus, S. A., & Williamson, M. K. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.5.817 · Cited by 301
Jamal, S. A., Bauer, D. C., Ensrud, K. E., Cauley, J. A., Hochberg, M., Ishani, A., & Cummings, S. R. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070112 · Cited by 301
Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis
Khan, S. A., Kanis, J. A., Vasikaran, S., Kline, W. F., Matuszewski, B. K., McCloskey, E. V., Beneton, M. N. C., Gertz, B. J., Sciberras, D. G., Holland, S. D., et al. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.10.1700 · Cited by 293
STEWART, A. F., VIGNERY, A., SILVERGLATE, A., RAVIN, N. D., LiVOLSI, V., BROADUS, A. E., & BARON, R. (1982) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-55-2-219 · Cited by 287
Self-citationSeeman, E., Delmas, P. D., Hanley, D. A., Sellmeyer, D., Cheung, A. M., Shane, E., Kearns, A., Thomas, T., Boyd, S. K., Boutroy, S., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.81 · Cited by 286
Redlich, K., Hayer, S., Maier, A., Dunstan, C. R., Tohidast‐Akrad, M., Lang, S., Türk, B., Pietschmann, P., Woloszczuk, W., Haralambous, S., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10097 · Cited by 285
Local communication on and within bone controls bone remodeling
Henriksen, K., Neutzsky-Wulff, A. V., Bonewald, L. F., & Karsdal, M. A. (2009) · Bone · doi:10.1016/j.bone.2009.03.671 · Cited by 282
(BONE), F. T. O. I. O. V. F. T. I. N. A. A. E., Delmas, P. D., Recker, R. R., Chesnut, C. H., Skag, A., Stakkestad, J. A., Emkey, R., Gilbride, J., Schimmer, R. C., & Christiansen, C. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1602-9 · Cited by 279
Kamiya, N., Ye, L., Kobayashi, T., Mochida, Y., Yamauchi, M., Kronenberg, H. M., Feng, J. Q., & Mishina, Y. (2008) · Development · doi:10.1242/dev.025825 · Cited by 275
Osteonecrosis of the Jaw in a Patient on Denosumab
Aghaloo, T. L., Felsenfeld, A. L., & Tetradis, S. (2010) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.10.010 · Cited by 275
Frith, J. C., M�nkk�nen, J., Auriola, S., M�nkk�nen, H., & Rogers, M. J. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200109)44:9<2201::aid-art374>3.0.co;2-e · Cited by 268
Bachmann, M. F., Wong, B. R., Josien, R., Steinman, R. M., Oxenius, A., & Choi, Y. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.7.1025 · Cited by 260
Delmas, P. D., Adami, S., Strugala, C., Stakkestad, J. A., Reginster, J., Felsenberg, D., Christiansen, C., Civitelli, R., Drezner, M. K., Recker, R. R., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21918 · Cited by 258
Sorensen, O. H., Crawford, G. M., Mulder, H., Hosking, D. J., Gennari, C., Mellstrom, D., Pack, S., Wenderoth, D., Cooper, C., & Reginster, J.-Y. (2003) · Bone · doi:10.1016/s8756-3282(02)00946-8 · Cited by 254
Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies
Reid, I. R., Miller, P. D., Brown, J. P., Kendler, D. L., Fahrleitner-Pammer, A., Valter, I., Maasalu, K., Bolognese, M. A., Woodson, G., Bone, H., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.149 · Cited by 251
Comparison of the distribution of 3H-alendronate and 3H-Etidronate in rat and mouse bones
Masarachia, P., Weinreb, M., Balena, R., & Rodan, G. A. (1996) · Bone · doi:10.1016/8756-3282(96)00182-2 · Cited by 248
Do osteocytes contribute to bone mineral homeostasis? Osteocytic osteolysis revisited
Teti, A., & Zallone, A. (2009) · Bone · doi:10.1016/j.bone.2008.09.017 · Cited by 245
Thompson, K., Rogers, M. J., Coxon, F. P., & Crockett, J. C. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.020776 · Cited by 242
Osteonecrosis of the jaws induced by anti-RANK ligand therapy
Taylor, K. H., Middlefell, L. S., & Mizen, K. D. (2010) · British Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.bjoms.2009.08.030 · Cited by 228
Invited Review: Pathogenesis of osteoporosis
Seeman, E. (2003) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00564.2003 · Cited by 222
Gerstenfeld, L. C., Sacks, D. J., Pelis, M., Mason, Z. D., Graves, D. T., Barrero, M., Ominsky, M. S., Kostenuik, P. J., Morgan, E. F., & Einhorn, T. A. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081113 · Cited by 218
Statins Prevent Bisphosphonate-Induced γ,δ-T-Cell Proliferation and Activation In Vitro
Thompson, K., & Rogers, M. J. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301230 · Cited by 217
Plotkin, L. I., Lezcano, V., Thostenson, J., Weinstein, R. S., Manolagas, S. C., & Bellido, T. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080617 · Cited by 214
Bisphosphonates: Molecular Mechanisms of Action and Effects on Bone Cells, Monocytes and Macrophages
J. Roelofs, A., Thompson, K., H. Ebetino, F., J. Rogers, M., & P. Coxon, F. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210793563635 · Cited by 202
Fogelman, I., Ribot, C., Smith, R., Ethgen, D., Sod, E., & Reginster for the bmd-mn Study Grou, J.-Y. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.5.6603 · Cited by 198
Bisphosphonates in cancer therapy
Stresing, V., Daubiné, F., Benzaid, I., Mönkkönen, H., & Clézardin, P. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.07.007 · Cited by 196
RANK, RANKL and osteoprotegerin in bone biology and disease
Wright, H. L., McCarthy, H. S., Middleton, J., & Marshall, M. J. (2009) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-009-9046-7 · Cited by 194
Ashcroft, A. J., Cruickshank, S. M., Croucher, P. I., Perry, M. J., Rollinson, S., Lippitt, J. M., Child, J. A., Dunstan, C., Felsburg, P. J., Morgan, G. J., et al. (2003) · Immunity · doi:10.1016/s1074-7613(03)00326-1 · Cited by 182
Molecular regulation of osteoclast activity
Bruzzaniti, A., & Baron, R. (2006) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-006-9009-x · Cited by 173
Self-citationDo RANKL inhibitors (denosumab) affect inflammation and immunity?
Ferrari, S., & Ferrari, S. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1326-y · Cited by 170
Self-citationMolecular Mechanisms in Coupling of Bone Formation to Resorption
Martin, T. J., Gooi, J. H., & Sims, N. A. (2009) · Critical Reviews™ in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v19.i1.40 · Cited by 167
Roelofs, A. J., Coxon, F. P., Ebetino, F. H., Lundy, M. W., Henneman, Z. J., Nancollas, G. H., Sun, S., Blazewska, K. M., Bala, J. L. F., Kashemirov, B. A., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.091009 · Cited by 163
Khosla, S., Melton, L. J., Robb, R. A., Camp, J. J., Atkinson, E. J., Oberg, A. L., Rouleau, P. A., & Riggs, B. L. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041228 · Cited by 162
Plotkin, L. I., Manolagas, S. C., & Bellido, T. (2006) · Bone · doi:10.1016/j.bone.2006.02.060 · Cited by 162
Reitsma, P. H., Bijvoet, O. L. M., Verlinden-Ooms, H., & van der Wee-Pals, L. J. A. (1980) · Calcified Tissue International · doi:10.1007/bf02408534 · Cited by 161
Helas, S., Goettsch, C., Schoppet, M., Zeitz, U., Hempel, U., Morawietz, H., Kostenuik, P. J., Erben, R. G., & Hofbauer, L. C. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080957 · Cited by 159
Allen, M. R., & Burr, D. B. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070720 · Cited by 148
Clinical development of anti-RANKL therapy
Schwarz, E. M., & Ritchlin, C. T. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2171 · Cited by 140
Safety Considerations with Bisphosphonates for the Treatment of Osteoporosis
Strampel, W., Emkey, R. D., & Civitelli, R. (2007) · Drug Safety · doi:10.2165/00002018-200730090-00003 · Cited by 139
Ominsky, M. S., Li, X., Asuncion, F., Barrero, M., Warmington, K. S., Dwyer, D., Stolina, M., Geng, Z., Grisanti, M. S., Tan, H., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080109 · Cited by 138
Prevention of glucocorticoid‐induced bone loss in mice by inhibition of RANKL
Hofbauer, L. C., Zeitz, U., Schoppet, M., Skalicky, M., Schüler, C., Stolina, M., Kostenuik, P. J., & Erben, R. G. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24445 · Cited by 137
Bisphosphonate and Nonbisphosphonate-Associated Osteonecrosis of the Jaw
Almazrooa, S. A., & Woo, S. (2009) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2009.0280 · Cited by 133
Vesicular trafficking in osteoclasts
Coxon, F. P., & Taylor, A. (2008) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2008.08.004 · Cited by 133
Pettway, G. J., Meganck, J. A., Koh, A. J., Keller, E. T., Goldstein, S. A., & McCauley, L. K. (2008) · Bone · doi:10.1016/j.bone.2007.11.017 · Cited by 133
Denosumab: Anti-RANKL antibody
Miller, P. D. (2009) · Current Osteoporosis Reports · doi:10.1007/s11914-009-0004-5 · Cited by 127
Inhibitory Immunoglobulin-Like Receptors LILRB and PIR-B Negatively Regulate Osteoclast Development
Mori, Y., Tsuji, S., Inui, M., Sakamoto, Y., Endo, S., Ito, Y., Fujimura, S., Koga, T., Nakamura, A., Takayanagi, H., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4742 · Cited by 126
Bone safety of long-term bisphosphonate treatment
Rodan, G. A., Reszka, A. A., Golub, E. E., & Rizzoli, R. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004475 · Cited by 125
Niida, S., Kondo, T., Hiratsuka, S., Hayashi, S., Amizuka, N., Noda, T., Ikeda, K., & Shibuya, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503544102 · Cited by 125
Recker, R. R., Marín, F., Ish‐Shalom, S., Moericke, R., Hawkins, F. G., Kapetanos, G., de la Peña, M. P., Kekow, J., Farrerons, J., Sanz, B., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090315 · Cited by 121
Calcifications in the Abdominal Aorta Predict Fractures in Men: MINOS Study
Szulc, P., Kiel, D. P., & Delmas, P. D. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070903 · Cited by 119
Komatsubara, S., Mori, S., Mashiba, T., Ito, M., Li, J., Kaji, Y., Akiyama, T., Miyamoto, K., Cao, Y., Kawanishi, J., et al. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.3.512 · Cited by 118
Komatsubara, S., Mori, S., Mashiba, T., Li, J., Nonaka, K., Kaji, Y., Akiyama, T., Miyamoto, K., Cao, Y., Kawanishi, J., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040126 · Cited by 117
Fas/CD95 is associated with glucocorticoid-induced osteocyte apoptosis
Kogianni, G., Mann, V., Ebetino, F. H., NUTTALL, M. E., Nijweide, P. J., Simpson, H., & Noble, B. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.04.048 · Cited by 110
RANK-Fc: A therapeutic antagonist for RANK-L in myeloma
Sordillo, E. M., & Pearse, R. N. (2003) · Cancer · doi:10.1002/cncr.11134 · Cited by 109
Gasser, J. A., Ingold, P., Venturiere, A., Shen, V., & Green, J. R. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.071207 · Cited by 107
Capparelli, C., Morony, S., Warmington, K., Adamu, S., Lacey, D., Dunstan, C. R., Stouch, B., Martin, S., & Kostenuik, P. J. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.5.852 · Cited by 103
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
Russell, R. G. G. (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s8054 · Cited by 102
Self-citationKhosla, S., Riggs, B. L., Robb, R. A., Camp, J. J., Achenbach, S. J., Oberg, A. L., Rouleau, P. A., & Melton, L. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0396 · Cited by 101
Elford, P. R., Felix, R., Cecchini, M. G., Trechsel, U., & Fleisch, H. A. (1987) · Calcified Tissue International · doi:10.1007/bf02563795 · Cited by 99
van Beek, E. R., Löwik, C. W. G. M., Que, I., & Papapoulos, S. E. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650111016 · Cited by 94
Recombinant Osteoprotegerin for Juvenile Paget's Disease
Cundy, T., Davidson, J. S., Rutland, M. D., Stewart, C., & DePaoli, A. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050893 · Cited by 93
Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading
Follet, H., Li, J., Phipps, R. J., Hui, S. L., Condon, K. W., & Burr, D. B. (2006) · Bone · doi:10.1016/j.bone.2006.12.052 · Cited by 90
Genant, H. K., Engelke, K., Hanley, D. A., Brown, J. P., Omizo, M., Bone, H. G., Kivitz, A., Fuerst, T. P., Wang, H., Austin, M., et al. (2010) · Bone · doi:10.1016/j.bone.2010.04.594 · Cited by 89
Renal Tolerability Profile of Novel, Potent Bisphosphonates in Two Short‐Term Rat Models
Green, J. R., Seltenmeyer, Y., Jaeggi, K. A., & Widler, L. (1997) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1997.tb01964.x · Cited by 87
Role of bone turnover in microdamage
Schaffler, M. B. (2003) · Osteoporosis International · doi:10.1007/s00198-003-1477-1 · Cited by 87
Stolina, M., Schett, G. A., Dwyer, D., Vonderfecht, S. L., Middleton, S. C., Duryea, D., Pacheco, E., Van, G. Y., Bolon, B. N., Feige, U., et al. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2879 · Cited by 86
Bone microdamage: a clinical perspective
Chapurlat, R. D., & Delmas, P. D. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0899-9 · Cited by 85
Are Osteoclasts Needed for the Bone Anabolic Response to Parathyroid Hormone?
Pierroz, D. D., Bonnet, N., Baldock, P. A. J., Ominsky, M. S., Stolina, M., Kostenuik, P. J., & Ferrari, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.101964 · Cited by 85
Self-citationRisedronate reduces intracortical porosity in women with osteoporosis
Borah, B., Dufresne, T. E., Nurre, J., Phipps, R. J., Chmielewski, P. A., Wagner, L. K., Lundy, M. W., Bouxsein, M., Zebaze, R., & Seeman, E. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090711 · Cited by 83
Ste‐Marie, L., Sod, E. W., Johnson, T. D., & Chines, A. A. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0039-7 · Cited by 81
Samadfam, R., Xia, Q., & Goltzman, D. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060915 · Cited by 80
Räikkönen, J., Crockett, J. C., Rogers, M. J., Mönkkönen, H., Auriola, S. O. K., & Mönkkönen, J. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00160.x · Cited by 78
Dobnig, H., Stepan, J. J., Burr, D. B., Li, J., Michalská, D., Sipos, A. A., Petto, H., Fahrleitner‐Pammer, A., & Pavo, I. J. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090527 · Cited by 74
Cremers, S., Sparidans, R. W., den Hartigh, J., Hamdy, N. A. T., Vermeij, P., & Papapoulos, S. E. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-001-0411-8 · Cited by 71
Li, X., Ominsky, M. S., Stolina, M., Warmington, K. S., Geng, Z., Niu, Q., Asuncion, F., Tan, H., Grisanti, M. S., Dwyer, D., et al. (2009) · Bone · doi:10.1016/j.bone.2009.06.011 · Cited by 68
Inhibitory effects of bisphosphonate (YM175) on bone resorption induced by a metastatic bone tumor
Hiraga, T., Tanaka, S., Yamamoto, M., Nakajima, T., & Ozawa, H. (1996) · Bone · doi:10.1016/8756-3282(95)00428-9 · Cited by 66
Byrne, F. R., Morony, S., Warmington, K., Geng, Z., Brown, H. L., Flores, S. A., Fiorino, M., Yin, S. L., Hill, D., Porkess, V., et al. (2004) · Gut · doi:10.1136/gut.2003.035113 · Cited by 65
Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolutionin vitro
Henneman, Z. J., Nancollas, G. H., Ebetino, F. H., Russell, R. G. G., & Phipps, R. J. (2007) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.31599 · Cited by 64
Self-citationTat, S. K., Padrines, M., Theoleyre, S., Couillaud-Battaglia, S., Heymann, D., Redini, F., & Fortun, Y. (2006) · Bone · doi:10.1016/j.bone.2006.03.016 · Cited by 63
Inhibition of RANKL as a treatment for osteoporosis: Preclinical and early clinical studies
McClung, M. R. (2006) · Current Osteoporosis Reports · doi:10.1007/s11914-006-0012-7 · Cited by 62
Fuchs, R. K., Shea, M., Durski, S., Winters‐Stone, K. M., Widrick, J. J., & Snow, C. M. (2007) · Bone · doi:10.1016/j.bone.2007.04.179 · Cited by 61
Bock, O., Börst, H., Thomasius, F. E., Degner, C., Stephan-Oelkers, M., Valentine, S. M., & Felsenberg, D. (2007) · PubMed · Cited by 61
Schett, G. A., Middleton, S. C., Bolon, B. N., Stolina, M., Brown, H., Zhu, L., Pretorius, J., Zack, D. J., Kostenuik, P. J., & Feige, U. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21021 · Cited by 58
Ominsky, M. S., Kostenuik, P. J., Cranmer, P., Smith, S. Y., & Atkinson, J. E. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0363-7 · Cited by 55
Mechanical properties in long bones of rat osteopetrotic mutations
Jämsä, T. J., Rho, J. Y., Fan, Z., MacKay, C. A., Marks, S. C., & Tuukkanen, J. (2002) · Journal of Biomechanics · doi:10.1016/s0021-9290(01)00203-2 · Cited by 55
Ominsky, M. S., Stolina, M., Li, X., Corbin, T. J., Asuncion, F., Barrero, M., Niu, Q., Dwyer, D., Adamu, S., Warmington, K. S., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090215 · Cited by 45
Skeletal Microdamage: Less About Biomechanics and More About Remodeling
Allen, M. R., & Burr, D. B. (2008) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-008-9015-5 · Cited by 43
Lespessailles, É., Jaffré, C., Beaupied, H., Nanyan, P., Dolleans, E., Benhamou, C. L., & Courteix, D. (2009) · Calcified Tissue International · doi:10.1007/s00223-009-9269-z · Cited by 41
Bijvoet, O. L. M. (1995) · Elsevier eBooks · Cited by 38
Recker, R. R., Ste‐Marie, L., Langdahl, B. L., Czerwinski, E. J., Bonvoisin, B., Masanauskaite, D., Rowell, L., & Felsenberg, D. (2009) · Bone · doi:10.1016/j.bone.2009.11.004 · Cited by 35
Ohishi, M., Chiusaroli, R., Ominsky, M. S., Asuncion, F., Thomas, C., Khatri, R., Kostenuik, P. J., & Schipani, E. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.081026 · Cited by 34
Lambert, C., Oury, C., Dejardin, E., Chariot, A., Piette, J. G., Malaise, M., Merville, M., & Franchimont, N. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070508 · Cited by 33
Clinical Disorders of Bone Resorption
Russell, R. G. G., Mueller, G., Shipman, C. M., & Croucher, P. I. (2001) · Novartis Foundation symposium · doi:10.1002/0470846658.ch17 · Cited by 32
Self-citationVerdrengh, M., Bokarewa, M. I., Ohlsson, C., Stolina, M., & Tarkowski, A. (2009) · Bone · doi:10.1016/j.bone.2009.10.028 · Cited by 32
Srivastava, T., Haney, C. J., & Alon, U. S. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081016 · Cited by 32
Johnston, S., Andrews, S., Shen, V., Cosman, F., Lindsay, R., Dempster, D. W., & Iida‐Klein, A. (2007) · Endocrinology · doi:10.1210/en.2007-0229 · Cited by 32
EPHs and ephrins: Many pathways to regulate osteoblasts and osteoclasts
Sims, N. A. (2010) · IBMS BoneKEy · doi:10.1138/20100463 · Cited by 11
Low Bone Turnover and Microdamage? How and Where to Assess It?
Burr, D. B., & Allen, M. R. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080307 · Cited by 10
Ferrari, S. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1250-1 · Cited by 10
Self-citationNitrogen-containing bisphosphonates and human γδ T cells
Benzaïd, I., & Clézardin, P. (2010) · IBMS BoneKEy · doi:10.1138/20100450 · Cited by 5
Cited by
Ruggiero, S. L., Dodson, T. B., Fantasia, J., Goodday, R., Aghaloo, T., Mehrotra, B., & O'Ryan, F. (2014) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2014.04.031 · Cited by 2,905
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Self-citationBisphosphonates: The first 40years
Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2011.04.022 · Cited by 1,124
Self-citationKhosla, S., Oursler, M. J., & Monroe, D. G. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.03.008 · Cited by 943
Macedo, F., Ladeira, K., Pinho, F., Saraiva, N., Bonito, N., Pinto, L., & Gonçalves, F. (2017) · Oncology Reviews · doi:10.4081/oncol.2017.321 · Cited by 775
Metadata
- Authors
- Baron, R., Ferrari, S., & Russell, R. G. G.
- Venue
- Bone
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 48
- Issue
- 4
- Pages
- 677-692
- ISSN
- 1873-2763 (ISSN-L)
- 8756-3282
- OpenAlex
- W1997823019
- Cited by
- 715
- References
- 174
- FWCI
- 27.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.